Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study.

Woods, Scott W; Tully, Elizabeth M; Walsh, Barbara C; Hawkins, Keith A; Callahan, Jennifer L; Cohen, Shuki J; Mathalon, Daniel H; Miller, Tandy J; McGlashan, Thomas H

Woods, Scott W; Tully, Elizabeth M; Walsh, Barbara C; Hawkins, Keith A; Callahan, Jennifer L; Cohen, Shuki J; Mathalon, Daniel H; Miller, Tandy J; McGlashan, Thomas H.

Affiliation

Woods SW; Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA. scott.woods@yale.edu

Br J Psychiatry Suppl ; 51: s96-101, 2007 Dec.

Article in En | MEDLINE | ID: mdl-18055946

Subject(s)

Antipsychotic Agents/therapeutic use; Piperazines/therapeutic use; Quinolones/therapeutic use; Schizotypal Personality Disorder/drug therapy; Adolescent; Adult; Antipsychotic Agents/administration & dosage; Antipsychotic Agents/adverse effects; Aripiprazole; Cognition/drug effects; Drug Administration Schedule; Female; Humans; Male; Neuropsychological Tests; Pilot Projects; Piperazines/administration & dosage; Piperazines/adverse effects; Psychiatric Status Rating Scales; Quinolones/administration & dosage; Quinolones/adverse effects; Schizotypal Personality Disorder/psychology; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Schizotypal Personality Disorder / Antipsychotic Agents / Quinolones Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male Language: En Year: 2007 Type: Article

Fulltext

XML

PubMed Links

Search on Google